

IFW



Attorney Docket No.: 6680.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Johansen et al.

Application No.: 10/822,020

Group Art Unit: To be assigned

Filed: April 9, 2004

Examiner: To be assigned

For: **PREVENTION OF HYPERINSULINEMIA IN SUBJECTS UNDERGOING GROWTH HORMONE (GH) TREATMENT**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. Segerlantz et. al., J Clin Endocrinol Metab, Vol. 86, No. 12, pages 5813-5818 (2001)
2. Nielsen et. al., Diabetes, Vol. 50, pages 2301-2308 (2001)


3. Piatti, et. al., J Clin Endocrinol Metab, Vol. 84, No. 5, pages 1658-1663 (1999)
4. Nam, et. al., Int J Obes, Vol. 25, pages 1101-1107 (2001)
5. Mamlöf, et. al., Horm Metab Res, Vol. 35, pages 236-242 (2003)
6. Sturiale, et. al., Horm Res, Vol. 48, supplement, page 190 (1997)
7. Metcalfe, et. al., Diabetologia, Vol. 20, pages 123-128 (1981)
8. Nielsen, S. Growth Horm IGF Res, Vol. 12, pages 425-433 (2002)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Respectfully submitted,

Date: July 19, 2004



Reza Green, Reg. No. 38,475
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE



Attorney Docket No.: 6680.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Johansen et al.

Serial No.: 10/822,020

Group Art Unit: To be assigned

Filed: April 9, 2004

Examiner: To be assigned

For: **PREVENTION OF HYPERINSULINEMIA IN SUBJECTS UNDERGOING GROWTH HORMONE (GH) TREATMENT**

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:


1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on **July 19, 2004**


Csaba Attila Szakolczai
(name of person mailing paper)


(signature of person mailing paper)

Use the following customer number for all correspondence regarding this application

23650

PATENT TRADEMARK OFFICE

	FORM ITO-449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Atty. Docket No. 6680.200-US	Serial No. 10/822,020
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
	Filing Date April 9, 2004		Group To be assigned	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Segerlantz et. al., J Clin Endocrinol Metab, Vol. 86, No. 12, pages 5813-5818 (2001)
		Nielsen et. al., Diabetes, Vol. 50, pages 2301-2308 (2001)
		Piatti, et. al., J Clin Endocrinol Metab, Vol. 84, No. 5, pages 1658-1663 (1999)
		Nam, et. al., Int J Obes, Vol. 25, pages 1101-1107 (2001)
		Mamlöf, et. al., Horm Metab Res, Vol. 35, pages 236-242 (2003)
		Sturiale, et. al., Horm Res, Vol. 48, supplement, page 190 (1997)
		Metcalfe, et. al., Diabetologia, Vol. 20, pages 123-128 (1981)
		Nielsen, S. Growth Horm IGF Res, Vol. 12, pages 425-433 (2002)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.